Drug pipeline
Full profile accessExplore the programs pursuing this target and their development progress.
- Drug candidates
- Developers
- Development stage
Target intelligence / Profile preview
Sulfatase-modifying factor 1 (SUMF1) is an essential enzyme responsible for a unique post-translational modification required for the catalytic activity of all sulfatases in humans. Located in the endoplasmic reticulum, SUMF1 (also known as formylglycine-generating enzyme, FGE) converts a conserved cysteine residue of the sulfatases into a C-alpha-formylglycine, the catalytic residue necessary for hydrolysis of sulfate esters. Deficiency or mutations in SUMF1 result in multiple sulfatase deficiency, a fatal lysosomal storage disorder characterized by neurologic, skeletal, and dermal abnormalities due to global impairment of all sulfatases. SUMF1 is regulated by protein-protein interactions, intracellular trafficking, and post-translational modifications. Beyond rare genetic disease, altered SUMF1 expression is also associated with cancer and inflammation, but there are no approved drugs directly targeting SUMF1.
Enhancement of sulfatase activation (in the context of potential gene therapy co-delivery with sulfatase cDNA)
Beyond the preview
Explore the evidence, development activity, and competitive landscape with Gosset’s full data platform.
Explore the programs pursuing this target and their development progress.
Follow the clinical studies evaluating therapies directed at this target.
Compare approaches across drug candidates, modalities, and indications.
Investigate the research and source evidence behind target biology and development.
Explore patent activity around therapies and technologies addressing this target.
Connect target biology, drug development, and emerging evidence in your research.
See how Gosset can support your research on Sulfatase-modifying factor 1 (SUMF1).